Evidence map›Paper›PMID 28796416›Full record

Trial reportClinical and translational science2017

Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men.

L Caro, J de Hoon, M Depré, C Cilissen, J Miller, W Gao, D Panebianco, Z Guo, S L Troemel, M S Anderson and 4 more

Abstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

L CaroMerck & Co., Inc., Kenilworth, New Jersey, USA.
J de HoonCenter for Clinical Pharmacology, University Hospitals, Leuven, Belgium.
M DepréCenter for Clinical Pharmacology, University Hospitals, Leuven, Belgium.
C CilissenMerck Sharp & Dohme (Europe) Inc., Brussels, Belgium.
J MillerMerck & Co., Inc., Kenilworth, New Jersey, USA.
W GaoMerck & Co., Inc., Kenilworth, New Jersey, USA.
D PanebiancoMerck & Co., Inc., Kenilworth, New Jersey, USA.
Z GuoMerck & Co., Inc., Kenilworth, New Jersey, USA.
S L TroemelMerck & Co., Inc., Kenilworth, New Jersey, USA.
M S AndersonMerck & Co., Inc., Kenilworth, New Jersey, USA.
N UemuraMerck & Co., Inc., Kenilworth, New Jersey, USA.
J ButtertonMerck & Co., Inc., Kenilworth, New Jersey, USA.
J WagnerMerck & Co., Inc., Kenilworth, New Jersey, USA.
D H WrightMerck & Co., Inc., Kenilworth, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaniprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. The aim of these double-blind, placebo-controlled phase I studies was to evaluate the safety and pharmacokinetics of vaniprevir in healthy male volunteers. The primary objective for both studies was the safety and tolerability of vaniprevir. Single-dose and steady-state pharmacokinetics were also assessed. In both studies, there was no apparent relationship between the frequency or intensity of adverse events and vaniprevir dose. At single doses >20 mg, the plasma area under the curve (AUC)

Indexed as

HealthAdministration, OralAdultArea Under CurveCyclopropanesDose-Response Relationship, DrugFastingHumansIndolesIsoindolesLactams, MacrocyclicLeucineMaleProlineSulfonamidesYoung AdultCyclopropanesIndolesIsoindolesLactams, MacrocyclicLeucineProlineSulfonamidesvaniprevir

Identifiers

PMID28796416
PMCPMC6402189

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.